Genmab A/S/€GMAB
1D1W1MYTD1Y5YMAX
Capital at risk
About Genmab A/S
Genmab A/S is a biotechnology company based in Copenhagen, Denmark, with a focus on developing innovative antibody therapeutics for the treatment of cancer. The company's core products include a range of proprietary technologies and therapeutic antibodies, most notably DARZALEX (daratumumab), which is used in the treatment of multiple myeloma. Genmab collaborates with various pharmaceutical companies to advance its research and expand its product offerings. Founded in 1999, the company leverages its proprietary antibody technologies, including the DuoBody and HexaBody platforms, to create differentiated therapies. Its strategic partnerships and emphasis on cutting-edge research provide it with a notable position in the biopharmaceutical industry.
- Ticker
- €GMAB
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 3,119
- Headquarters
- Copenhagen, Denmark
- Website
- www.genmab.com
Genmab A/S Metrics
BasicAdvanced
€17B
26.78
€10.96
0.69
-
Price and volume
Market cap
€17B
Beta
0.69
52-week high
€306.20
52-week low
€203.00
Average daily volume
111K
Financial strength
Current ratio
2.457
Quick ratio
2.441
Long term debt to equity
0.833
Total debt to equity
0.885
Interest coverage (TTM)
4.96%
Profitability
EBITDA (TTM)
1,192.757
Gross margin (TTM)
93.03%
Net profit margin (TTM)
19.08%
Operating margin (TTM)
32.29%
Effective tax rate (TTM)
13.02%
Revenue per employee (TTM)
€1,143,380
Management effectiveness
Return on assets (TTM)
8.79%
Return on equity (TTM)
14.00%
Valuation
Price to earnings (TTM)
26.78
Price to revenue (TTM)
5.052
Price to book
21.55
Price to tangible book (TTM)
-39.25
Price to free cash flow (TTM)
24.043
Free cash flow yield (TTM)
4.16%
Free cash flow per share (TTM)
12.205
Growth
Revenue change (TTM)
22.26%
Earnings per share change (TTM)
-36.79%
3-year revenue growth (CAGR)
18.55%
10-year revenue growth (CAGR)
34.68%
3-year earnings per share growth (CAGR)
5.57%
10-year earnings per share growth (CAGR)
22.19%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.